Last €1.41 EUR
Change Today +0.012 / 0.86%
Volume 0.0
DYBN On Other Exchanges
As of 1:03 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

discovery laboratories inc (DYBN) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/28/14 - €1.96
52 Week Low
12/10/14 - €0.84
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

discovery laboratories inc (DYBN) Related Businessweek News

No Related Businessweek News Found

discovery laboratories inc (DYBN) Details

Discovery Laboratories, Inc., a specialty biotechnology company, focuses on developing life-saving products for critical-care patients with respiratory disease and care in pulmonary medicine. Its drug technology produces a synthetic peptide-containing surfactant (KL4 surfactant), as well as in liquid, lyophilized, and aerosolized dosage forms; and develops drug delivery technologies to enable efficient delivery of its aerosolized KL4 surfactant. The company’s product includes SURFAXIN Intratracheal suspension for the prevention of respiratory distress syndrome (RDS) in premature infants. It is also developing AEROSURF, a drug-device combination product that is in Phase IIa clinical trials for the treatment of RDS in premature infants; and AFECTAIR devices, which are novel disposable aerosol-conducting airway connectors for infants. The company has a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of KL4 surfactant products in Andorra, Greece, Italy, Portugal, and Spain. Discovery Laboratories, Inc. was founded in 1992 and is headquartered in Warrington, Pennsylvania.

126 Employees
Last Reported Date: 03/17/14
Founded in 1992

discovery laboratories inc (DYBN) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $493.3K
Chief Operating Officer and Senior Vice Presi...
Total Annual Compensation: $380.3K
Senior Vice President, General Counsel and Co...
Total Annual Compensation: $303.5K
Total Annual Compensation: $336.3K
Compensation as of Fiscal Year 2013.

discovery laboratories inc (DYBN) Key Developments

Discovery Laboratories Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Provides Operating Cash Outflows Guidance for the Fourth Quarter of 2014

Discovery Laboratories Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported total revenue of $527,000 compared to $60,000 a year ago. Operating loss was $10,327,000 compared to $10,813,000 a year ago. Net loss was $11,324,000 or $0.13 per basic and diluted share compared to $12,224,000 or $0.22 per basic and diluted share a year ago. Net cash outflows before financing activities for the quarter ended September 30, 2014 were $10.6 million. For the nine months period, the company reported total revenue of $1,651,000 compared to $315,000 a year ago. Operating loss was $32,032,000 compared to $34,242,000 a year ago. Net loss was $33,423,000 or $0.41 per diluted share compared to $33,486,000 or $0.69 per diluted share a year ago. For the fourth quarter of 2014, the company anticipates operating cash outflows before financing activities of approximately $11 million.

Discovery Laboratories Inc. Announces Executive Changes

Discovery Laboratories Inc. announced organizational changes to the development leadership team and a special advisory appointment to augment the company's expertise in neonatology and aerosolized drug delivery. Steven G. Simonson, M.D., has been appointed Senior Vice President and Chief Development Officer, with responsibility for research, clinical development, aerosol device development, regulatory affairs, and patient safety /pharmacovigilance. Dr. Simonson joined Discovery Labs in May 2014 as Vice President, Clinical Development, and brings to Discovery Labs over 25 years of medical practice and pharmaceutical industry clinical trial experience with a significant focus in pulmonary critical care and developing respiratory drugs. The company also announced the appointment of Jan Mazela, M.D., Ph.D. as Special Medical and Scientific Advisor - Neonatology. Dr. Mazela is a pediatrician and neonatologist, a global key opinion leader in neonatology, and an expert in the application of aerosolization technology to neonatal medicine. He currently serves as Medical Director in the Department of Neonatology and Infectious Diseases at Poznan University of Medical Sciences in Poznan, Poland. As part of the organizational changes, Russell G. Clayton, D.O., Discovery Labs' Senior Vice President, Research and Development will be leaving the company by mutual agreement in December 2014 to pursue other interests. He will serve in an advisory role to the company through the planned AEROSURF phase 2 program.

Discovery Laboratories Inc. to Report Q3, 2014 Results on Nov 06, 2014

Discovery Laboratories Inc. announced that they will report Q3, 2014 results at 9:00 AM, Eastern Standard Time on Nov 06, 2014


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DYBN:GR €1.41 EUR +0.012

DYBN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $47.37 USD -0.24
View Industry Companies

Industry Analysis


Industry Average

Valuation DYBN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 80.6x
Price/Book 4.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 37.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DISCOVERY LABORATORIES INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at